On disclosed annual figures, the operating loss widened from KRW 6.37 billion in 2024 to KRW 8.6 billion in 2025, a continued loss that deepened year on year, and the company has posted losses in two consecutive years from 2024 to 2025.
The net loss attributable to controlling shareholders grew from KRW 6.04 billion in 2024 to KRW 8.05 billion in 2025, and the consolidated net loss including non-controlling interests was also KRW 6.04 billion in 2024 and KRW 8.05 billion in 2025.
Operating cash flow went from -KRW 4.49 billion in 2024 to -KRW 6.34 billion in 2025, so the cash outflow grew.
The debt ratio rose from 5.6% in 2024 to 8.1% in 2025, and at the end of 2025 total equity was KRW 14.3 billion, of which controlling shareholders' equity was also KRW 14.3 billion, with total liabilities of KRW 1.15 billion. The quarterly series has no figures for Q3 and Q4 2025, so it starts in Q1 2026.
The operating loss was KRW 1.91 billion in Q1 2026, KRW 2.49 billion in Q2 and KRW 2.66 billion in Q3, a loss that widened each quarter.
Net losses attributable to controlling shareholders over the same period were KRW 1.82 billion, KRW 2.26 billion and KRW 2.52 billion, moving in the same direction as operating losses.
The four quarterly net losses attributable to controlling shareholders from Q1 to Q4 2025 total KRW 8.05 billion, the same as the annual figure for 2025. With no revenue, costs are the main driver of the loss, so the size of the loss is likely to be sensitive to the intensity of clinical and approval activity.
Cost line items, however, need to be checked in the notes to the regular report. Because the disclosed series starts in 2024, the long-term trend can only be read across two years, and Q4 2026 results are expected to be disclosed in the 2026 annual report.